| 產品名稱 |
VLN3G2 |
| 商品貨號 |
B165927 |
| Organism |
human (B cell); human (myeloma) |
| Cell Type |
hybridoma: B lymphocyte |
| Product Format |
frozen |
| Morphology |
lymphoblast |
| Culture Properties |
suspension |
| Biosafety Level |
2 CELLS CONTAIN HERPESVIRUS
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease |
a regional draining lymph node of a patient with carcinoma of the vulva. |
| Storage Conditions |
liquid vapor phase |
| Disclosure |
This material is cited in a US or other Patent and may not be used to
infringe the claims. Depending on the wishes of the Depositor, ATCC may be
required to inform the Patent Depositor of the party to which the material was
furnished. This material may not have been produced or characterized by ATCC. |
| Derivation |
Lymphocytes were isolated from a regional draining lymph node of a patient with carcinoma of the vulva. B lymphocytes were fused with UC 729-6 cells (see ATCC CRL-8061). |
| Clinical Data |
Lymphocytes were isolated from a regional draining lymph node of a patient with carcinoma of the vulva. |
| Genes Expressed |
immunoglobulin; monoclonal antibody; against cancer of the vulva |
| Cellular Products |
immunoglobulin; monoclonal antibody; against cancer of the vulva |
| Comments |
Lymphocytes were isolated from a regional draining lymph node of a patient with carcinoma of the vulva. B lymphocytes were fused with UC 729-6 cells (see ATCC CRL-8061). The antibody recognizes an epitope on a 78000 dalton antigen on A-431 cells and a 66000 dalton antigen on T293H cells. |
| Complete Growth Medium |
The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, ATCC 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum (ATCC 30-2020) to a final concentration of 10%.
|
| Subculturing |
Protocol: Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 X 10 exp5 viable cells/ml. Maintain cell density between 1 X 10 exp5 and 5 X 10 exp5 viable cells/ml.
Medium Renewal: Every 2 days |
| Cryopreservation |
Freeze medium: Complete growth medium 95%; DMSO, 5% Storage temperature: liquid vapor phase |
| Culture Conditions |
Temperature: 37.0°C |
| Isotype |
IgG4 |
| Name of Depositor |
Regents of the University of California |
| U.S. Patent Number |
|
| References |
Glassy MC, Surh C. Human-human hybrid cell lines that produce antibodies against antigenic determinants on cancer cells. US Patent 4,761,377 dated Aug 2 1988
|
